H1Bh1bdatabase.info

Employer profile

Epic Pharma

3 certified H-1B filings across 3 fiscal years.

FY2025 filings
1
FY2025 median
$98k
Top role
Human Resource Associate
1 filings
Top state
NY
3 filings

Epic Pharma has filed 3 certified H-1B Labor Condition Applications over FY2021–FY2025. In FY2025, its median certified base salary was $98k ($98k–$98k interquartile range). The most-filed role is Human Resource Associate (1 filings).

Year-over-year

How Epic Pharma hired across H-1B fiscal years. YoY column compares to the prior FY.

FYFilingsMedian $YoY %
FY20251$98k0
FY20231$55k0
FY20211$100k

Top job titles

Most-filed positions, across all years (raw DOL titles).

Job TitleFilingsMedian
Human Resource Associate1$55k
Quality Control Chemist1$98k

Top worksite states

Where this employer files.

StateFilingsMedian
NY3$98k

Prevailing wage level distribution

DOL Levels I–IV approximate experience tiers (I = entry, IV = fully competent). A heavy Level I/II skew suggests entry-level / contractor-style hiring; a heavy IV skew suggests senior in-house roles.

Lvl I
267%
Lvl III
133%

Frequently asked questions

Does Epic Pharma sponsor H-1B visas?
Yes. Epic Pharma has filed 3 certified H-1B Labor Condition Applications (LCAs) over FY2021–FY2025. An LCA is a required step before an employer files an H-1B petition; a certified LCA does not by itself guarantee an approved visa.
What is the median H-1B salary at Epic Pharma?
In FY2025, the median certified H-1B base salary at Epic Pharma was $98k, with a 25th–75th percentile range of $98k–$98k. This is the annual base wage stated on the LCA and excludes bonus, equity, and other compensation.
What jobs does Epic Pharma hire H-1B workers for?
Epic Pharma's most-filed H-1B role is Human Resource Associate (1 filings), followed by Quality Control Chemist (1). Its top worksite state is NY.
How many H-1B filings did Epic Pharma submit in FY2025?
Epic Pharma had 1 certified H-1B LCA filings in FY2025 — a level reading from the prior fiscal year.
Browse all 3 filings →Just FY2025